---
title: "Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288433689.md"
description: "Bluejay Diagnostics (BJDX) stock surged over 184% in premarket trading after signing a strategic partnership with Argonaut Manufacturing Services. The agreement aims to expand U.S. manufacturing capabilities for its Symphony sepsis testing platform, enhancing supply chain resilience and reducing reliance on overseas production. Despite the rally, BJDX remains down significantly year-to-date and over the past year. TipRanks' AI analyst Spark rates the stock as Neutral with a $1.50 price target, citing weak financial performance."
datetime: "2026-06-02T13:13:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288433689.md)
  - [en](https://longbridge.com/en/news/288433689.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288433689.md)
---

# Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?

Bluejay Diagnostics (BJDX) stock underwent an extreme rally on Tuesday after the medical diagnostics company signed an agreement with Argonaut Manufacturing Services. The two companies have agreed to a strategic partnership that will see Argonaut Manufacturing Services support the development of Bluejay Diagnostics' Symphony platform. Symphony is a testing system for sepsis triage and monitoring of disease progression.

### Claim 55% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Bluejay Diagnostics noted that this agreement is designed to expand its U.S. manufacturing capabilities. The company hopes that this will strengthen its future commercial infrastructure and enhance supply chain resilience. Doing so would help prevent the company from having to deal with the effects of tariffs and international trade. This would be a major change for Bluejay Diagnostics, which largely relies on overseas manufacturing.

Neil Dey, president and CEO of Bluejay Diagnostics, was pleased with the strategic partnership with Argonaut Manufacturing Services. He said it "reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones."

## **Bluejay Diagnostics Stock Movement Today**

Bluejay Diagnostics stock was up 184.33% in premarket trading on Tuesday, following a 1.4% rally yesterday. However, the stock has fallen 18.67% year-to-date and 69.52% over the past 12 months.

BJDX stock trading activity today was strong, as some 33 million shares changed hands. For comparison, the company's three-month average daily trading volume was about 5.27 million shares.

## **Is Bluejay Diagnostics Stock a Buy, Sell, or Hold?**

Turning to Wall Street, traditional analyst coverage of Bluejay Diagnostics stock is lacking. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates BJDX stock as Neutral with a $1.50 price target. It cites "very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn)" as reasons for this stance.

### Related Stocks

- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)

## Related News & Research

- [Bluejay Diagnostics Raises $7.7 Million in Private Placement, Issues Pre-Funded and 5-Year Warrants](https://longbridge.com/en/news/289105229.md)
- [COIN Stock Alert: What to Know as Coinbase Launches AI Trading Tool](https://longbridge.com/en/news/289629146.md)
- [2 hypergrowth pure-play AI stocks to buy and hold for the next decade](https://longbridge.com/en/news/289371960.md)
- [The AI Proxy Nobody Realized They Owned](https://longbridge.com/en/news/289455650.md)
- [KPMG pulls report on AI usage due to apparent hallucinations](https://longbridge.com/en/news/289673426.md)